Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem ® is a trademark of Actinogen Medical.

ToplineAs recession fears reverberate from Washington to Wall Street, Wednesday will bring the most comprehensive yardstick ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...